Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy

Great hopes have been placed on human pluripotent stem (hPS) cells for therapy. Tissues or organs derived from hPS cells could be the best solution to cure many different human diseases, especially those who do not respond to standard medication or drugs, such as neurodegenerative diseases, heart fa...

Full description

Saved in:
Bibliographic Details
Main Authors: Casimir de Rham, Jean Villard
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2014/518135
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832560581287084032
author Casimir de Rham
Jean Villard
author_facet Casimir de Rham
Jean Villard
author_sort Casimir de Rham
collection DOAJ
description Great hopes have been placed on human pluripotent stem (hPS) cells for therapy. Tissues or organs derived from hPS cells could be the best solution to cure many different human diseases, especially those who do not respond to standard medication or drugs, such as neurodegenerative diseases, heart failure, or diabetes. The origin of hPS is critical and the idea of creating a bank of well-characterized hPS cells has emerged, like the one that already exists for cord blood. However, the main obstacle in transplantation is the rejection of tissues or organ by the receiver, due to the three main immunological barriers: the human leukocyte antigen (HLA), the ABO blood group, and minor antigens. The problem could be circumvented by using autologous stem cells, like induced pluripotent stem (iPS) cells, derived directly from the patient. But iPS cells have limitations, especially regarding the disease of the recipient and possible difficulties to handle or prepare autologous iPS cells. Finally, reaching standards of good clinical or manufacturing practices could be challenging. That is why well-characterized and universal hPS cells could be a better solution. In this review, we will discuss the interest and the feasibility to establish hPS cells bank, as well as some economics and ethical issues.
format Article
id doaj-art-1c4b3fd385fe4ec3a69bdd540a38360d
institution Kabale University
issn 2314-8861
2314-7156
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-1c4b3fd385fe4ec3a69bdd540a38360d2025-02-03T01:27:11ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/518135518135Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell TherapyCasimir de Rham0Jean Villard1Transplant Immunology Unit, Division of Immunology and Allergy and Division of Laboratory Medicine, University Hospital of Geneva, 4 rue Gabrielle Perret-Gentil, 1211 Geneva 14, SwitzerlandTransplant Immunology Unit, Division of Immunology and Allergy and Division of Laboratory Medicine, University Hospital of Geneva, 4 rue Gabrielle Perret-Gentil, 1211 Geneva 14, SwitzerlandGreat hopes have been placed on human pluripotent stem (hPS) cells for therapy. Tissues or organs derived from hPS cells could be the best solution to cure many different human diseases, especially those who do not respond to standard medication or drugs, such as neurodegenerative diseases, heart failure, or diabetes. The origin of hPS is critical and the idea of creating a bank of well-characterized hPS cells has emerged, like the one that already exists for cord blood. However, the main obstacle in transplantation is the rejection of tissues or organ by the receiver, due to the three main immunological barriers: the human leukocyte antigen (HLA), the ABO blood group, and minor antigens. The problem could be circumvented by using autologous stem cells, like induced pluripotent stem (iPS) cells, derived directly from the patient. But iPS cells have limitations, especially regarding the disease of the recipient and possible difficulties to handle or prepare autologous iPS cells. Finally, reaching standards of good clinical or manufacturing practices could be challenging. That is why well-characterized and universal hPS cells could be a better solution. In this review, we will discuss the interest and the feasibility to establish hPS cells bank, as well as some economics and ethical issues.http://dx.doi.org/10.1155/2014/518135
spellingShingle Casimir de Rham
Jean Villard
Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
Journal of Immunology Research
title Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_full Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_fullStr Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_full_unstemmed Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_short Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_sort potential and limitation of hla based banking of human pluripotent stem cells for cell therapy
url http://dx.doi.org/10.1155/2014/518135
work_keys_str_mv AT casimirderham potentialandlimitationofhlabasedbankingofhumanpluripotentstemcellsforcelltherapy
AT jeanvillard potentialandlimitationofhlabasedbankingofhumanpluripotentstemcellsforcelltherapy